Comprehensive pharmacogenomic characterization of gastric cancer
Open accessThe DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Abstract
Background: Gastric cancer is among the most lethal human malignancies. Previous studies have identified molecular aberrations that constitute dynamic biological networks and genomic complexities of gastric tumors. However, the clinical translation of molecular-guided targeted therapy is hampered by challenges. Notably, solid tumors often harbor multiple genetic alterations, complicating the development of effective treatments. Methods: To address such challenges, we established a comprehensive dataset of molecularly annotated patient derivatives coupled with pharmacological profiles for 60 targeted agents to explore dynamic pharmacogenomic interactions in gastric cancers. Results: We identified lineage-specific drug sensitivities based on histopathological and molecular subclassification, including substantial sensitivities toward VEGFR and EGFR inhibition therapies in diffuse- and signet ring-type gastric tumors, respectively. We identified potential therapeutic opportunities for WNT pathway inhibitors in ALK-mutant tumors, a significant association between PIK3CA-E542K mutation and AZD5363 response, and transcriptome expression of RNF11 as a potential predictor of response to gefitinib. Conclusions: Collectively, our results demonstrate the feasibility of drug screening combined with tumor molecular characterization to facilitate personalized therapeutic regimens for gastric tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The large-scale pharmacogenetic study using a drug sensitivity dataset based on patient-derived GC specimens identified the lineage-specific drug sensitivities, including the effect of epidermal growth factor receptor inhibitors for signet-ring cells, vascular endothelial growth factor receptor inhibitors for diffuse-type tumors, PARP inhibitors for tumors with BRCA2 mutation, WNT inhibitors for”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van der Togt, H. (2003) · Journal of Network and Computer Applications · doi:10.1016/s1084-8045(02)00061-9 · Cited by 303,775
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Self-citation
Cited by
Matsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“…the effect of epidermal growth factor receptor inhibitors for signet-ring cells, vascular endothelial growth factor receptor inhibitors for diffuse-type tumors, PARP inhibitors for tumors with BRCA2 mutation, WNT inhibitors for ALK-mutant tumors, and AKT blockade for PIK3CA-E542K mutation [68].”
BackgroundAn overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
Alharbi, K. S., Shaikh, M. A. J., Afzal, O., Altamimi, A. S. A., Almalki, W. H., Alzarea, S. I., Kazmi, I. A., Al-Abbasi, F. A., Singh, S. K., Dua, K., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110108 · Cited by 77
Gu, Z., Yao, Y., Yang, G., Zhu, G., Tian, Z., Wang, R., Wu, Q., Wang, Y., Wu, Y., Chen, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5987 · Cited by 84
Cao, X., Ge, S., Hua, W., Zhou, X., Lu, W., Gu, Y., Li, Z., & Qian, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01481-y · Cited by 56
“Moreover, the PIK3CA E542K mutation (G70271A in exon 9) is also common in GC [10].”
BackgroundSong, X.-H., Cai, H., Shi, Z., Li, Z., Zheng, X., Yang, K., Gong, Q., Gu, Z., Hu, J., & Luo, K. (2023) · Advanced Science · doi:10.1002/advs.202306230 · Cited by 43
Metadata
- Authors
- Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., Kim, S., Kim, K.-M., Kim, S. T., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Her, N.-G., Lee, Y., Cho, H. J., Shin, Y. J., Kim, M., Koo, H., Kim, M., Seo, Y. J., Kim, J. Y., Choi, M.-G., Nam, D.-H., & Lee, J.
- Affiliations
- Korea University (KR)
- Samsung Medical Center (KR)
- Corresponding author
- Lee, Joon Ho
- Choi, Min-Gew
- Nam, Do-Hyun
- Lee, Jeeyun
- ORCID
- Venue
- Genome Medicine
- Published
- 2020-02-18
- Volume
- 12
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1756-994X (ISSN-L)
- PMC
- PMC7029441
- OpenAlex
- W3011823531
- Cited by
- 46
- References
- 76
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 7 · 2022: 14 · 2021: 9 · 2020: 4
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Genome Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Health and Welfare (HI14C3418)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- gastric cancer, pharmacogenomics, drug sensitivity, targeted therapy, VEGFR inhibitors, EGFR inhibitors, diffuse-type gastric cancer, signet ring cell carcinoma, Wnt pathway inhibitors, ALK mutations, AZD5363, gefitinib, RNF11, drug screening, personalized treatment
- MeSH terms
- Pharmacogenomic Variants, Gefitinib, Antineoplastic Agents, DNA-Binding Proteins, Humans, Mutation, Pyrimidines, Pyrroles, Stomach Neoplasms, Tumor Cells, Cultured, Drug Resistance, Neoplasm, Receptors, Vascular Endothelial Growth Factor, Cell Line, Tumor, Protein Kinase Inhibitors, Class I Phosphatidylinositol 3-Kinases, Transcriptome, Wnt Signaling Pathway, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive pharmacogenomic characterization of gastric cancer. https://app.cochat.ai/papers/10.1186/s13073-020-0717-8
- The paper
- Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., Kim, S., Kim, K.-M., Kim, S. T., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Her, N.-G., Lee, Y., . . . Lee, J. (2020). Comprehensive pharmacogenomic characterization of gastric cancer. Genome Medicine. https://doi.org/10.1186/s13073-020-0717-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.